Everest Medicines (STU:6HN) Shares Outstanding (EOP): 351.3 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6HN Everest Medicines Ltd STU:6HN
51 GF Score
Price €2.80
GF Value €32.66
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Shares Outstanding (EOP)?

Everest Medicines STU:6HN -0.71% 51 Shares Outstanding (EOP) is 351.3 Mil as of Dec. 2025. GuruFocus rates STU:6HN with a GF Score™ of 51/100 and a GF Value™ of €32.66 (Possible Value Trap). The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Everest Medicines's shares outstanding for the quarter that ended in Dec. 2025 was 351.3 Mil.

Everest Medicines's quarterly shares outstanding increased from Jun. 2025 (327.4 Mil) to Dec. 2025 (351.3 Mil). It means Everest Medicines issued new shares from Jun. 2025 to Dec. 2025 .

Everest Medicines's annual shares outstanding increased from Dec. 2024 (324.3 Mil) to Dec. 2025 (351.3 Mil). It means Everest Medicines issued new shares from Dec. 2024 to Dec. 2025 .


Everest Medicines  (STU:6HN) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Everest Medicines Shares Outstanding (EOP) Related Terms


Everest Medicines Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Everest Medicines's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Shares Outstanding (EOP) Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 294.41 305.46 319.36 324.35 351.34

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 319.36 322.29 324.35 327.43 351.34

STU:6HN vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Everest Medicines's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Shares Outstanding (EOP) falls into.


STU:6HN
51GF Score
Everest Medicines Ltd STU:6HN
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Everest Medicines Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 351.3 Mil mean?
Everest Medicines (STU:6HN) has a Shares Outstanding (EOP) of 351.3 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Everest Medicines and its competitors.
Is Everest Medicines' Shares Outstanding (EOP) too high?
Everest Medicines' current Shares Outstanding (EOP) is 351.3 Mil. Overall, Everest Medicines has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Shares Outstanding (EOP) compare to VRTX and REGN?
Everest Medicines' Shares Outstanding (EOP) of 351.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Everest Medicines and its competitors. Everest Medicines's current Shares Outstanding (EOP) is 351.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (STU:6HN) is currently considered Possible Value Trap. The stock's GF Value™ is €32.66, compared to a current price of €2.80 — trading 91.4% below its estimated fair value. The current Shares Outstanding (EOP) is 351.3 Mil. Everest Medicines' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Everest Medicines (STU:6HN), the current Shares Outstanding (EOP) is 351.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Everest Medicines (STU:6HN) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of €2.80 is trading 91.4% below its estimated GF Value™ of €32.66. GuruFocus considers Everest Medicines to be Possible Value Trap.

Key valuation signals for STU:6HN:

  • Shares Outstanding (EOP): 351.3 Mil
  • GF Value™: €32.66 vs. price of €2.80 (91.4% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:6HN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Everest Medicines Business Description

Other Exchanges 01952:Hong Kong
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
51GF Score

Get the complete analysis for STU:6HN

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.80
Price
€32.66
GF Value